Aller au contenu principal

 Articles scientifiques

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Année : 2019
Journal : Eur J Cancer
Volume : 114
Pages : 55-66

pAKT pathway activation is associated with <i>PIK3CA</i> mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.

Auteurs : Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 7

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Auteurs : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Auteurs : Curigliano G, de Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM
Année : 2019
Journal : Oncologist

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Auteurs : Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 371-382

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Auteurs : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : JCI Insight
Volume : 5

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Auteurs : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 3209-3218

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Auteurs : Kotecki N, Gombos A, Awada A
Année : 2019
Journal : Expert Rev Anticancer Ther
Volume : 19
Pages : 447-454

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Auteurs : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Année : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Auteurs : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

Auteurs : Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN
Année : 2019
Journal : J Clin Oncol
Pages : JCO1900739

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.

Auteurs : Rossi G, Ignatiadis M
Année : 2019
Journal : Cancer Res
Volume : 79
Pages : 2798-2804

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Auteurs : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.

Auteurs : Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S
Année : 2019
Journal : Acta Clin Belg
Pages : 1-5

Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.

Auteurs : Lambertini M, Viglietti G, de Azambuja E
Année : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 43-51

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.

Auteurs : Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud W, Canon JL, Gombos A, Dalenc F, Delaloge S, Lemonnier J, Loussouarn D, Verrièle V, Campone M
Année : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 65

Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer.

Auteurs : Genot-Klastersky MT, Paesmans M, Ameye L, Kayumba A, Beauvois S, Dragan T, Van Gestel D, Lalami Y, Klastersky JA
Année : 2019
Journal : Support Care Cancer

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Auteurs : Tuyaerts S, Van Nuffel AMT, Naert E, van Dam PA, Vuylsteke P, De Caluwe A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H
Année : 2019
Journal : BMC Cancer
Volume : 19
Pages : 506

FOLFIRI as second-line treatment of metastatic biliary tract cancer patients.

Auteurs : Caparica R, Lengelé A, Bekolo W, Hendlisz A
Année : 2019
Journal : Autops Case Rep
Volume : 9
Pages : e2019087

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316